Thrombophilia in coronary artery disease: a double jeopardy.
Thrombophilia can be defined as an increased risk of thrombosis. The central event to the pathogenesis of any thrombotic episode is the perturbation of haemostasis, the cause of which may be genetic or environmental. The clinical manifestations of the chronic development of coronary artery atheroma are angina and acute myocardial infarction. In recent years literature is emerging on the role of different factors of blood coagulation in arterial thrombosis. Different coagulation factors, natural anticoagulants, platelet antigens and other factors such as homocysteine, lipoprotein (a), have been studied as risk factors for coronary artery disease (CAD). The results of many of these studies are contradictory. In India, there is an alarming rise in the number of young patients with myocardial infarction (MI) and an interesting feature is that a large majority of these patients lack the conventional risk factors. There have been scattered studies on the thrombophilia status among Indians. The management of thrombophilia can be done by a regimen of different drugs which has been evaluated in different clinical trials. Since the cost of thrombophilia investigations is quite phenomenal for a developing country like India, the selection of these investigations assumes an utmost importance.
Institute of Immunohaematology (ICMR), Mumbai, India. mohanty@bom5.vsnl.net.in
D
D
Mohanty
K
K
Ghosh
A
A
Khare
B
B
Kulkarni
D015415:Biomarkers / Q000032:analysis; D003324:Coronary Artery Disease / Q000150:complications*; D006801:Humans; D007194:India; D009203:Myocardial Infarction / Q000150:complications; D019851:Thrombophilia / Q000150:complications* / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy
D015415:Biomarkers